Live Breaking News & Updates on Veronica gambillara fonck

Stay informed with the latest breaking news from Veronica gambillara fonck on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Veronica gambillara fonck and stay connected to the pulse of your community

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

SCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Nov 2, 2023--

Zurich , Züsz , Switzerland , Elias-papatheodorou , Mike-sinclair , Veronica-gambillara-fonck , Pureos-bioventures , Gf-group , Vesalius-biocapital , Adjuvant-capital , Verve-ventures , Schroders-capital

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Developm

Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase IIISCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced to...

Switzerland , Zurich , Züsz , Veronica-gambillara-fonck , Pureos-bioventures , Elias-papatheodorou , Mike-sinclair , Gf-group , Memo-therapeutics , Vesalius-biocapital , Adjuvant-capital , Verve-ventures

Memo Therapeutics raises $27.7 million to develop antibody treatment

The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.

Japan , Japanese , Pureos-bioventures , Veronica-gambillara-fonck , Drug-administration , Vesalius-biocapital , Fast-track , Vera-therapeutics , Bio-developments , Arkets-amp-regulations , Ipelines , Ntibody-drug-conjugates

GlycoEra AG Appoints Ganesh V. Kaundinya as President and Chief Executive Officer

/PRNewswire/ -- GlycoEra AG announced today the appointment of Ganesh V. Kaundinya, Ph.D. as President and Chief Executive Officer. Dr. Kaundinya has been a...

Boston , Massachusetts , United-states , Zurich , Züsz , Switzerland , Massachusetts-institute-of-technology , Graziano-seghezzi , Monique-schiersing , Veronica-gambillara-fonck , Robert-langer , Baxter-baxalta

GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform

Financing round co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners with participation from LimmaTech Biologics AG GlycoEra AG announced today the close of a CHF 45 million ($49 million)

Boston , Massachusetts , United-states , Milan , Lombardia , Italy , Paris , France-general- , France , South-san-francisco , California , Switzerland